Abstract
Plasma homocysteine concentration exhibits a strong relationship with (indices of) renal function. Hyperhomocysteinemia has been implicated in the high vascular event rate in patients with chronic renal failure. The precise pathophysiological explanation for the occurrence of hyperhomocysteinemia in renal failure is not yet elucidated. A defective intrinsic renal metabolism of homocysteine seems unlikely. There are several indications that whole body homocysteine metabolism is altered in renal insufficiency. Stable isotope studies in dialysis patients have shown a decreased homocysteine clearance by transsulfuration and decreased homocysteine remethylation and methionine transmethylation. Several, but not all, prospective studies have linked hyperhomocysteinemia to adverse cardiovascular outcomes in renal failure patients. Treatment of hyperhomocysteinemia in renal insufficiency is based on folic acidcontaining regimens, but so far, none of the regimens has been shown to successfully normalize plasma homocysteine concentration. Intervention studies have not yet demonstrated beneficial vascular effects of homocysteine-lowering treatment in dialysis patients.
Keywords: homocysteine, hyperhomocysteinemia, renal insufficiency, amino acid metabolism
Current Drug Metabolism
Title: Homocysteine and the Kidney
Volume: 6 Issue: 1
Author(s): Coen van Guldener
Affiliation:
Keywords: homocysteine, hyperhomocysteinemia, renal insufficiency, amino acid metabolism
Abstract: Plasma homocysteine concentration exhibits a strong relationship with (indices of) renal function. Hyperhomocysteinemia has been implicated in the high vascular event rate in patients with chronic renal failure. The precise pathophysiological explanation for the occurrence of hyperhomocysteinemia in renal failure is not yet elucidated. A defective intrinsic renal metabolism of homocysteine seems unlikely. There are several indications that whole body homocysteine metabolism is altered in renal insufficiency. Stable isotope studies in dialysis patients have shown a decreased homocysteine clearance by transsulfuration and decreased homocysteine remethylation and methionine transmethylation. Several, but not all, prospective studies have linked hyperhomocysteinemia to adverse cardiovascular outcomes in renal failure patients. Treatment of hyperhomocysteinemia in renal insufficiency is based on folic acidcontaining regimens, but so far, none of the regimens has been shown to successfully normalize plasma homocysteine concentration. Intervention studies have not yet demonstrated beneficial vascular effects of homocysteine-lowering treatment in dialysis patients.
Export Options
About this article
Cite this article as:
Guldener van Coen, Homocysteine and the Kidney, Current Drug Metabolism 2005; 6 (1) . https://dx.doi.org/10.2174/1389200052997410
DOI https://dx.doi.org/10.2174/1389200052997410 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design New Technologies: Non-Hormonal Female Contraception
Current Women`s Health Reviews Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research Genetic and Non-Genetic Determinants of the Pharmacological Activity of Statins
Current Drug Metabolism Breathing Generation and Potential Pharmacotherapeutic Approaches to Central Respiratory Disorders
Current Medicinal Chemistry Insulin Resistance-Induced Hypertension and a Role of Perivascular CGRPergic Nerves
Current Protein & Peptide Science A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque Rupture
Current Vascular Pharmacology Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) P2X Receptors and Diabetes
Current Medicinal Chemistry Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology The Role of Oxidative Stress in Cerebral Aneurysm Formation and Rupture
Current Neurovascular Research Guidelines and their Implementation: A Discussion Document Focused on the Best Approaches to Drive Improvement
Vascular Disease Prevention (Discontinued) Treatment of Foot Disease in Patients with Type 2 Diabetes Mellitus using Human Umbilical Cord Blood Mesenchymal Stem Cells: Response and Correction of Immunological Anomalies
Current Pharmaceutical Design Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Current Drug Metabolism Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design